Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares

Posted by George Bondi on Aug 20th, 2026

Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the transaction, the chief technology officer directly owned 76,865 shares in the company, valued at $922,380. This represents a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Seshu Tyagarajan also recently made the following trade(s):

On Monday, June 29th, Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $70,140.00.

Candel Therapeutics Stock Performance

Shares of NASDAQ:CADL opened at $13.50 on Thursday. The company has a market cap of $1.03 billion, a P/E ratio of -9.57 and a beta of -0.51. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09. Candel Therapeutics, Inc. has a one year low of $4.35 and a one year high of $13.82. The business’s 50-day simple moving average is $9.93 and its 200 day simple moving average is $7.55.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). On average, sell-side analysts forecast that Candel Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Candel Therapeutics

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in shares of Candel Therapeutics in the second quarter worth $63,000. BNP Paribas Financial Markets lifted its stake in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after acquiring an additional 4,439 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Candel Therapeutics in the 4th quarter worth about $51,000. Tower Research Capital LLC TRC boosted its position in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after acquiring an additional 7,527 shares during the period. Finally, Invesco Ltd. acquired a new stake in Candel Therapeutics during the 1st quarter worth about $59,000. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on CADL. Stifel Nicolaus initiated coverage on shares of Candel Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $22.00 target price for the company. Bank of America lifted their price target on Candel Therapeutics from $9.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, August 14th. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Candel Therapeutics in a report on Thursday, August 13th. Finally, UBS Group restated a “buy” rating on shares of Candel Therapeutics in a research report on Monday. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Candel Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $19.29.

Check Out Our Latest Research Report on CADL

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.